FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology
J Clin Transl Sci
.
2023 May 2;7(1):e101.
doi: 10.1017/cts.2023.515.
eCollection 2023.
Authors
Elizabeth S Russell
1
,
Elodie Aubrun
2
,
Daniela C Moga
3
,
Sandra Guedes
4
,
Wendy Camelo Castillo
5
,
Janet R Hardy
6
,
J Alexander Cole
7
,
Oladayo Jagun
8
Affiliations
1
Merck & Co., Inc., Rahway, NJ, USA.
2
Novartis Pharma AG, Basel, Switzerland.
3
University of Kentucky, College of Pharmacy, Lexington, KY, USA.
4
Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
5
University of Maryland School of Pharmacy, Baltimore, MD, USA.
6
Biohaven Pharmaceuticals Holding Company Ltd., New Haven, CT, USA.
7
Alexion - AstraZeneca Rare Disease, Boston, MA, USA.
8
Pfizer Inc., New York, NY, USA.
PMID:
37251002
PMCID:
PMC10225256
DOI:
10.1017/cts.2023.515
No abstract available
Keywords:
Trial diversity; epidemiology; real-world data.
Publication types
Editorial